Levels develops a health and wellness platform designed to monitor metabolic fitness. The platform tracks blood glucose in real-time, enabling users to optimize their diet and exercise. The company was founded in 2019 and is a remote-first company.
Vicinitas Therapeutics is a biotech startup that specializes in developing medicines that impact patient lives. Its vision is to use its proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform to restore the levels of aberrantly degraded proteins that cause disease to confer therapeutic benefit.
CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start to disease treatment, significantly reducing the time and risk to bring new medicines to patients.
BigHat is a developer of an AI-guided protein therapeutic platform used to integrate antibody characterization lab with machine learning technologies to engineer molecules with more complex functions and better biophysical properties. The company is applying these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.
Cartography is shaping a world in which cancer immunotherapies are designed around and directed toward the safest and most effective targets.
Ultima Genomics is unleashing the power of genomics at scale. Ultima Genomics drives the scale of genomic information to enable unprecedented advances in biology and improvements in human health. The company was founded in 2016 and is based in Newark, California.
Turquoise Health is a health tech company that provides simplification of administration to reduce the expense and complexity of healthcare using data from hospital and payer machine-readable files. The company provides a new marketplace for patients, providers, and payers that connects stakeholders across the aisle.
Octant Bio is a developer of synthetic technology used to improve health and treat disease. Its technology uses synthetic biology, genome engineering, next-generation sequencing, and computational tools to simultaneously measure the activity of thousands of receptor pathways in human cells that enable scientists to apply machine learning methods to engineer small molecules that interact with multiple receptors and unlock a new potential to treat complex diseases.
Deepcell provides software for single-cell dimensional morphology analysis. They also provide an AI-powered imaging and microfluidics platform that identifies and isolates viable cells based on morphological distinctions for use in translational research, diagnostic testing, and therapeutics.
Memora Health, the leading intelligent care enablement platform, helps clinicians focus on top-of-license practice while proactively engaging patients along complex care journeys. Memora partners with leading health systems, health plans, and digital health companies to transform the care delivery process for care teams and patients. Our platform digitizes and automates high-touch clinical workflows, supercharging care teams by intelligently triaging patient-reported concerns and data to appropriate care team members and providing patients with proactive, two-way communication and support. Memora Health is headquartered in San Francisco, CA, with clients and team members around the country, and is backed by Andreessen Horowitz, Transformation Capital, General Catalyst, AlleyCorp, Frist Cressey Ventures, Martin Ventures, Kevin Durant and Rich Kleiman's Thirty Five Ventures, and several other strategic healthcare groups. To learn more about Memora’s vision to make care more actionable, accessible and always-on, visit memorahealth.com.
Ventus Therapeutics is a biopharmaceutical company discovering and developing novel small molecule medicines that target the innate immune system to treat autoimmune diseases, inflammatory diseases, and cancer. Ventus' structural immunology platform offers unprecedented insight into mechanisms and molecular structures, combining core capabilities for precisely targeting the innate immune system: proprietary protein engineering capabilities that elucidate innate immune mechanisms, and leading-edge rational and structure-based drug design tools. Ventus has built an emerging pipeline of multiple drug programs addressing key targets in the innate immune system.
Topography Health encourages physicians in private practice to participate in clinical trials in order to advance medical research. Topography assists medical practices in better understanding their patient populations, recommending which studies are likely to be taken up and have an impact, recruiting patients, and hiring and managing research staff. Topography-powered local clinical trials give patients with a wide range of health conditions access to personalized clinical trials for the first time.
We believe everyone should have the opportunity to live their best lives and age with dignity. That’s why we’re reinventing primary care with an approach designed to profoundly improve the healthcare and aging experience for older adults and their loved ones.
Thyme Care is a healthcare company that provides oncology care management services. The company offers a patient- and provider-integrated oncology solution, partnering with health plans to facilitate whole-person care for their members. Thyme Care seeks to revolutionize cancer care by providing personalized and holistic support to patients. The company envisions a future where every cancer patient can access high-quality, individualized care that meets their unique needs and circumstances.
Pearl Health is powering the future of healthcare. We help primary care providers and organizations deliver quality healthcare to the patients who need it most, when they need it most — and get rewarded for keeping patients healthy. Our technology, services, and financial tools enable better, more proactive care, decrease total cost of care across patient panels, and optimize performance in value-based care models for Traditional Medicare and Medicare Advantage. We are a team of physicians and public health experts, technologists, healthcare innovators, and experienced risk management professionals who believe that primary care providers are the key to addressing our healthcare system’s biggest challenges. Since its founding in 2020, Pearl has expanded to partner with thousands of primary care providers in practices and organizations across 44 states. Our investors include Andreessen Horowitz, Viking Global Investors, AlleyCorp, and SV Angel.
CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start to disease treatment, significantly reducing the time and risk to bring new medicines to patients.
Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.
Tomorrow Health is a technology-driven home healthcare company changing the way individuals and families manage their care. It brings together personal service and modern technology to get their clients the products and supplies they need. Tomorrow Health connect providers, health plans, and home-based care suppliers, to ensure that patients can access care even in their home. Founded in 2018, the company is headquartered in New York, New York, United States.
Firefly Health provides primary health care services that redefine high-quality patient care. The company uses sophisticated technology with a thoughtful care team experience for continuous, intelligent care that changes behavior and drives value by providing virtual-first primary care approach, live video appointments with primary care physician and team for convenience without any membership fees, allowing people to make smart choices about their health, while enabling clinicians to provide unparalleled, consistent, and proactive care.
Komodo Health Inc. is a healthcare technology company that provides a platform for healthcare data aimed at enhancing decision-making and transparency in the industry. Founded in 2014 and headquartered in New York, with an additional office in San Francisco, the company offers various software applications, including Healthcare Map, which tracks patient outcomes across the healthcare system. Its solutions, such as Aperture, Pulse, and Serenity, deliver valuable insights by analyzing extensive data from patients, practitioners, and health systems. These applications enable health and life sciences enterprises to identify insights, address gaps in care, and reduce the burden of disease, thereby setting a new standard for real-world data and analytics in healthcare.
BigHat is a developer of an AI-guided protein therapeutic platform used to integrate antibody characterization lab with machine learning technologies to engineer molecules with more complex functions and better biophysical properties. The company is applying these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.
Deepcell provides software for single-cell dimensional morphology analysis. They also provide an AI-powered imaging and microfluidics platform that identifies and isolates viable cells based on morphological distinctions for use in translational research, diagnostic testing, and therapeutics.
BIOAGE discovers and develops drugs to treat aging and associated diseases. The company's primary initiative, azelaprag, is an oral APJ agonist on track for Phase 2 trials in conjunction with tirzepatide to potentially become a groundbreaking treatment for obesity in the elderly.
Levels develops a health and wellness platform designed to monitor metabolic fitness. The platform tracks blood glucose in real-time, enabling users to optimize their diet and exercise. The company was founded in 2019 and is a remote-first company.
FidoCure is transforming canine cancer care through AI-driven precision medicine. By harnessing data from naturally occurring canine cancers via next-generation sequencing and clinical information, FidoCure has developed the world's largest proprietary learning database for canine cancer. FidoCure is pioneering first-in-class care for canine cancer, which represents the largest unmet need for pet dogs. By connecting human and veterinary oncology, FidoCure enhances comparative oncology, improves outcomes across species, and creates new opportunities for drug development that benefit both pets and humans.
PatientPing is a health technology company that is building a national network of engaged providers who are sharing information, coordinating care, and working together to get patients healthier faster. PatientPing connects healthcare providers across the country with real-time notifications and care guidelines whenever and wherever their patients receive care. PatientPing's national care coordination network includes physicians, nurses, case managers, and care coordinators across hospitals, emergency departments, accountable care organizations (ACOs), physician practices, skilled nursing facilities, home health agencies, inpatient rehabilitation centers, and payers. By connecting care teams through real-time information sharing, PatientPing enables providers to deliver higher quality and more cost-effective care, improving patient outcomes, and experience.
Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.
Tomorrow Health is a technology-driven home healthcare company changing the way individuals and families manage their care. It brings together personal service and modern technology to get their clients the products and supplies they need. Tomorrow Health connect providers, health plans, and home-based care suppliers, to ensure that patients can access care even in their home. Founded in 2018, the company is headquartered in New York, New York, United States.
Devoted Health is an all-in-one healthcare company on a mission to dramatically improve the health and well-being of older Americans by caring for every person like family. To accomplish this, Devoted Health has designed and built an integrated healthcare solution that combines Devoted Health Medicare Advantage plans, access to top local providers alongside virtual and in-home care delivered by Devoted Medical, full-service guides, and world-class technology that powers it all.
Ribbon Health is a healthcare data platform that provides the critical infrastructure that payers, providers, and digital health solutions need to enable accurate provider directories, reliable referral management, and efficient care navigation.
Q Bio was founded in 2015 by Jeffrey Kaditz, serial entrepreneur and Founder of Affirm, Dr Michael Snyder, Chair of Genetics and Director of Personalized Medicine and Stanford University, and Dr Garry Choy, physician, radiologist, and former Chief Medical Information Officer at Mass General Hospital. Q Bio is fortunate to be backed by some of the best venture groups in the world including: A16Z, Khosla Ventures, Founders Fund, SciFi VC, and Kevin Durant. This interdisciplinary team based in San Carlos, CA is comprised of pioneers in fields such applied math, computational physics, electrical engineering, genetics, and radiology, hail from a dizzying array of home countries and cultural backgrounds.
Komodo Health Inc. is a healthcare technology company that provides a platform for healthcare data aimed at enhancing decision-making and transparency in the industry. Founded in 2014 and headquartered in New York, with an additional office in San Francisco, the company offers various software applications, including Healthcare Map, which tracks patient outcomes across the healthcare system. Its solutions, such as Aperture, Pulse, and Serenity, deliver valuable insights by analyzing extensive data from patients, practitioners, and health systems. These applications enable health and life sciences enterprises to identify insights, address gaps in care, and reduce the burden of disease, thereby setting a new standard for real-world data and analytics in healthcare.
Genesis Therapeutics is a company that has its roots in academic research, which serves as the foundational element of its growing portfolio of AI technologies. The company employs a combination of innovative deep neural networks, biophysical simulation techniques, and highly scalable computing infrastructure. This amalgamation of technologies is geared towards achieving remarkable results in molecular generation and property prediction, particularly in the field of drug discovery and molecular design. Established in 2019 and headquartered in South San Francisco, California, Genesis Therapeutics focuses on leveraging innovative AI methodologies to enhance the efficiency and accuracy of molecular research. The company's approach holds promise in revolutionizing how molecules are generated and analyzed, potentially leading to advancements in drug development and related fields.
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation and direction in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing toward the clinic personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease. The founding team includes experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, who collectively have an unparalleled track record of executing safe and effective cell and gene therapy clinical trials. In addition, Tmunity’s manufacturing platform has a proven track record of success in supporting multi-center clinical studies across diverse therapeutic indications.
Incredible Health is a career marketplace technology that connects health systems with nurses. Its mission is to help healthcare professionals live better lives and find and do the work. The AI technology custom matches the health system’s nurse hiring needs with experienced, permanent nurse talent for the hard-to-fill roles.
Their mission: to increase health literacy around the world Over the last 100 years, the world’s language literacy has increased significantly. Their challenge over the next 100 years is to increase the world’s health literacy. They believe the best way to create change is to celebrate the people who are dedicated to their health, rather than harass the people who are not. The Health Conscious are the unsung heroes — the people who don’t get credit for their hard work. Help us spread health literacy to every corner of the world.
BIOAGE discovers and develops drugs to treat aging and associated diseases. The company's primary initiative, azelaprag, is an oral APJ agonist on track for Phase 2 trials in conjunction with tirzepatide to potentially become a groundbreaking treatment for obesity in the elderly.
FidoCure is transforming canine cancer care through AI-driven precision medicine. By harnessing data from naturally occurring canine cancers via next-generation sequencing and clinical information, FidoCure has developed the world's largest proprietary learning database for canine cancer. FidoCure is pioneering first-in-class care for canine cancer, which represents the largest unmet need for pet dogs. By connecting human and veterinary oncology, FidoCure enhances comparative oncology, improves outcomes across species, and creates new opportunities for drug development that benefit both pets and humans.
Ciitizen’s mission is to provide Earth’s 7.3 billion citizens with control of their complete health information and give them the choice of sharing it with whomever they want. Period. With this new ownership, patients can share their health history with caregivers, share for second opinions, and with companies/researchers who may hold the answer to their treatment. All patients have a right to all of their health information, yet existing portals pull only minimal clinical information from a fraction of health care institutions. Current “interoperability” initiatives leave the patient out of the picture and often rely on armies of manual labor to extract key health insights from unstructured textual data—an expensive model which doesn’t scale. In the near future, citizens will walk into a clinical facility and, with a simple tap of a mobile device, release their health information to themselves, where Ciitizen normalizes unstructured data from across the healthcare ecosystem into actionable visualizations for patients, their caregivers, and clinicians. Ciitizen has assembled an all-star team, led by its CEO, Anil Sethi (last company was sold to Apple) and is backed by a strong investment team led by Andreessen Horowitz, Verily, Section 32 and others.
Ciitizen’s mission is to provide Earth’s 7.3 billion citizens with control of their complete health information and give them the choice of sharing it with whomever they want. Period. With this new ownership, patients can share their health history with caregivers, share for second opinions, and with companies/researchers who may hold the answer to their treatment. All patients have a right to all of their health information, yet existing portals pull only minimal clinical information from a fraction of health care institutions. Current “interoperability” initiatives leave the patient out of the picture and often rely on armies of manual labor to extract key health insights from unstructured textual data—an expensive model which doesn’t scale. In the near future, citizens will walk into a clinical facility and, with a simple tap of a mobile device, release their health information to themselves, where Ciitizen normalizes unstructured data from across the healthcare ecosystem into actionable visualizations for patients, their caregivers, and clinicians. Ciitizen has assembled an all-star team, led by its CEO, Anil Sethi (last company was sold to Apple) and is backed by a strong investment team led by Andreessen Horowitz, Verily, Section 32 and others.
CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start to disease treatment, significantly reducing the time and risk to bring new medicines to patients.
Aria Pharmaceuticals is a preclinical-stage pharmaceutical company discovering and developing novel small molecule therapies for complex and hard-to-treat diseases. Too many patients today are in need of breakthrough treatments across many complicated diseases – they can't wait. That's why at Aria, we have redefined the drug discovery approach, saving years in the process and increasing success rates 30 times higher than traditional methods. At Aria, we've shown promise across a diverse range of therapeutic areas with the ability to address over 1,000 diseases.
Q Bio was founded in 2015 by Jeffrey Kaditz, serial entrepreneur and Founder of Affirm, Dr Michael Snyder, Chair of Genetics and Director of Personalized Medicine and Stanford University, and Dr Garry Choy, physician, radiologist, and former Chief Medical Information Officer at Mass General Hospital. Q Bio is fortunate to be backed by some of the best venture groups in the world including: A16Z, Khosla Ventures, Founders Fund, SciFi VC, and Kevin Durant. This interdisciplinary team based in San Carlos, CA is comprised of pioneers in fields such applied math, computational physics, electrical engineering, genetics, and radiology, hail from a dizzying array of home countries and cultural backgrounds.
Deepcell provides software for single-cell dimensional morphology analysis. They also provide an AI-powered imaging and microfluidics platform that identifies and isolates viable cells based on morphological distinctions for use in translational research, diagnostic testing, and therapeutics.
Their mission: to increase health literacy around the world Over the last 100 years, the world’s language literacy has increased significantly. Their challenge over the next 100 years is to increase the world’s health literacy. They believe the best way to create change is to celebrate the people who are dedicated to their health, rather than harass the people who are not. The Health Conscious are the unsung heroes — the people who don’t get credit for their hard work. Help us spread health literacy to every corner of the world.
BIOAGE discovers and develops drugs to treat aging and associated diseases. The company's primary initiative, azelaprag, is an oral APJ agonist on track for Phase 2 trials in conjunction with tirzepatide to potentially become a groundbreaking treatment for obesity in the elderly.
At Shield, we’re ensuring that antibiotic resistance doesn’t become more deadly than cancer. In 2050 more people will be dying of antibiotic resistant pathogens than cancer. Infections that were once treatable with a simple oral antibiotics are now requiring complex, painful treatments and resulting in serious health complications for patients. Gonorrhea is one such infection, having become resistant to over 10 different antibiotics, they have only one treatment that is still effective and resistance to this has already begun to emerge. With 820,000 new infections every year in the US, antibiotic resistance will spread quickly, which is why the CDC has resistant gonorrhea at an urgent threat level, the highest level available. Shield's novel genomic testing platform enables STI clinics to identify the antibiotic resistant strains of gonorrhea and other pathogens that their patients have, so they can select the correct antibiotics and halt the spread of antibiotic resistance.
PatientPing is a health technology company that is building a national network of engaged providers who are sharing information, coordinating care, and working together to get patients healthier faster. PatientPing connects healthcare providers across the country with real-time notifications and care guidelines whenever and wherever their patients receive care. PatientPing's national care coordination network includes physicians, nurses, case managers, and care coordinators across hospitals, emergency departments, accountable care organizations (ACOs), physician practices, skilled nursing facilities, home health agencies, inpatient rehabilitation centers, and payers. By connecting care teams through real-time information sharing, PatientPing enables providers to deliver higher quality and more cost-effective care, improving patient outcomes, and experience.
Headquartered in South San Francisco, Jungla is a biotechnology company delivering robust and scalable results for clinical genetic and genomic testing. To achieve this, Jungla develops and combines advances in functional genomics, computational biophysics, and computer science to proactively inform on the risk of variants in our genome. Jungla aims to empower clinical genetic testing with quantitative, model-driven guidance to complement and enhance observational data. Whereas existing solutions routinely used in the market have demonstrably poor accuracies, Jungla delivers robust, scalable, and auditable support with dramatically higher accuracies and increasingly mechanistic cellular and biophysical insights. We are supported by leading technology and healthcare investors.
Benchling is the modern software platform purpose-built for life science R&D. Hundreds of thousands of scientists using cutting-edge techniques like CRISPR, CAR-T immunotherapy, and genetic engineering depend on our suite of cloud applications to design DNA, collaborate on experiments, manage research workflows, and make critical R&D decisions.
Q Bio was founded in 2015 by Jeffrey Kaditz, serial entrepreneur and Founder of Affirm, Dr Michael Snyder, Chair of Genetics and Director of Personalized Medicine and Stanford University, and Dr Garry Choy, physician, radiologist, and former Chief Medical Information Officer at Mass General Hospital. Q Bio is fortunate to be backed by some of the best venture groups in the world including: A16Z, Khosla Ventures, Founders Fund, SciFi VC, and Kevin Durant. This interdisciplinary team based in San Carlos, CA is comprised of pioneers in fields such applied math, computational physics, electrical engineering, genetics, and radiology, hail from a dizzying array of home countries and cultural backgrounds.
Aria Pharmaceuticals is a preclinical-stage pharmaceutical company discovering and developing novel small molecule therapies for complex and hard-to-treat diseases. Too many patients today are in need of breakthrough treatments across many complicated diseases – they can't wait. That's why at Aria, we have redefined the drug discovery approach, saving years in the process and increasing success rates 30 times higher than traditional methods. At Aria, we've shown promise across a diverse range of therapeutic areas with the ability to address over 1,000 diseases.
Human API is a real-time health data network that gives consumers a simple way to view and share their health data from everywhere - regardless of how or where that data was collected, processed, or stored. The company provides a single, secure connection to data from 90% of US hospitals, electronic medical records, pharmacies, and labs, along with 300+ wearable devices and wellness apps. Consumers are in full control of what companies they share their health data with, and companies have one easy way to access fragmented health data sources. It was founded in 2013 and is based in San Mateo, California.
Human API is a real-time health data network that gives consumers a simple way to view and share their health data from everywhere - regardless of how or where that data was collected, processed, or stored. The company provides a single, secure connection to data from 90% of US hospitals, electronic medical records, pharmacies, and labs, along with 300+ wearable devices and wellness apps. Consumers are in full control of what companies they share their health data with, and companies have one easy way to access fragmented health data sources. It was founded in 2013 and is based in San Mateo, California.
Science Exchange, Inc. operates an online marketplace designed to facilitate collaboration between researchers and scientific service providers, including academic and government laboratories. Founded in 2011 and headquartered in Palo Alto, California, the platform allows researchers to search for scientific services, compare pricing, and access quality testimonials, streamlining the procurement process. Additionally, Science Exchange offers an enterprise dynamic report tool that helps pharmaceutical and biotechnology companies track key performance indicators related to their outsourced research and development investments. By automating various collaborative tasks such as obtaining quotes, managing projects, and processing payments, the marketplace enhances R&D productivity while ensuring data security and regulatory compliance.